Company: INKT
Filing Date: 2025-12-10
Form Type: S-3/A
Source: 0001193125-25-314252
Chunk: 36

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-12-10
Form: S-3/A
Chunk 36
---
 MiNK Therapeutics, Inc. and its
subsidiaries and their predecessors.

This prospectus supplement also includes trademarks, tradenames and service marks that are the
property of other organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus supplement appear without the and symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not
assert its rights, to these trademarks and tradenames.

S-ii

PROSPECTUS SUPPLEMENT SUMMARY

This summary highlights selected information about us, this offering and information appearing elsewhere in this prospectus supplement, in the accompanying prospectus and in the documents we incorporate by reference. This summary is not complete and does not contain all of the information you should consider before investing in our securities. Before making an investment decision, to fully understand this offering and its consequences to you, you should carefully read this entire prospectus supplement and the accompanying prospectus, including “Risk Factors” beginning on page S-5of this prospectus supplement and the financial statements and related notes and the other information that we incorporate by reference into this prospectus supplement.

Our Business

We are a clinical-stage
biopharmaceutical company developing first-in-class, off-the-shelf invariant natural
killer T (iNKT) cell therapies designed to treat cancer and immune-mediated diseases. Our therapies are based on a proprietary platform of allogeneic, ex-vivo expanded iNKT cells—cells that are designed
to uniquely combine the precision and memory of adaptive T cells with the speed and potency of natural killer (NK) cells. This rare biology is designed to allow iNKT cells to navigate tissues, eliminate tumors and infected cells, and reprogram the
immune environment—all without graft-versus-host disease (GVHD).

We believe iNKT cells represent an optimal platform for off-the-shelf cellular immunotherapy. Unlike conventional T or NK cell therapies, our iNKT cells can persist without lymphodepletion and function without the need for human
leukocyte antigen (HLA) matching. This allows for scalable, repeatable, and widely accessible treatment options in indications with significant unmet need.

Our approach includes the development of both native and engineered iNKT cell therapies. Our pipeline includes wholly owned and exclusively
licensed assets targeting solid tumors, pulmonary immune failure, and immune-related disorders. We have also developed a proprietary neoantigen library that supports personalized T